Pure Global AI
NCT06004869Not yet recruiting

Incorporating EMA and EMI Into CBT-I Using mHealth and Wearable Technologies

Incorporating Ecological Momentary Assessment and Intervention Into Cognitive Behavioural Therapy for Insomnia Using mHealth and Wearable Technologies: A Pilot Randomised Controlled Trial
Chinese University of Hong KongClinicalTrials.govbehavioral
Verified
Study focus
Disease/Condition
Insomnia
Drug/Device/Intervention
Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Chinese University of Hong Kong
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2023
End date
Dec 31, 2024
Enrollment
90 participants
Primary outcome

Changes in Insomnia Severity Index (ISI)

Summary

This study will be a randomised controlled trial to investigate an integrated platform that
 incorporates ecological momentary assessments/interventions (EMA/I) into cognitive
 behavioural therapy for insomnia (CBT-I) using mHealth and wearable technology. The
 intervention is a promising prospect to address current challenges in the context of sleep
 medicine to provide real-time and real-world intervention with accuracy, low cost, and easy
 accessibility.

ICD-10 classifications
Nonorganic insomniaDisorders of initiating and maintaining sleep [insomnias]Sleep disordersSleep disorder, unspecifiedOther sleep disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06004869
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06004869 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese University of Hong Kong and is currently Not yet recruiting. The study focuses on Insomnia. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.